JP2010528091A - ビンフルニンおよびトラスツズマブを含んでなる癌治療の組合せ療法 - Google Patents
ビンフルニンおよびトラスツズマブを含んでなる癌治療の組合せ療法 Download PDFInfo
- Publication number
- JP2010528091A JP2010528091A JP2010509824A JP2010509824A JP2010528091A JP 2010528091 A JP2010528091 A JP 2010528091A JP 2010509824 A JP2010509824 A JP 2010509824A JP 2010509824 A JP2010509824 A JP 2010509824A JP 2010528091 A JP2010528091 A JP 2010528091A
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- vinflunine
- trastuzumab
- weeks
- neoplasm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07290679A EP1997534A1 (de) | 2007-05-31 | 2007-05-31 | Kombinationstherapie zur Krebsbehandlung mit Vinflunin und Trastuzumab |
PCT/EP2008/056620 WO2008145697A1 (en) | 2007-05-31 | 2008-05-29 | Cancer treatment combination therapy comprising vinflunine and trastuzumab |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010528091A true JP2010528091A (ja) | 2010-08-19 |
JP2010528091A5 JP2010528091A5 (de) | 2011-07-14 |
Family
ID=38353425
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010509824A Withdrawn JP2010528091A (ja) | 2007-05-31 | 2008-05-29 | ビンフルニンおよびトラスツズマブを含んでなる癌治療の組合せ療法 |
Country Status (18)
Country | Link |
---|---|
US (1) | US20100196363A1 (de) |
EP (2) | EP1997534A1 (de) |
JP (1) | JP2010528091A (de) |
KR (1) | KR20100017752A (de) |
CN (1) | CN101687104A (de) |
AR (1) | AR066778A1 (de) |
AU (1) | AU2008257555A1 (de) |
BR (1) | BRPI0812280A2 (de) |
CA (1) | CA2689664A1 (de) |
CL (1) | CL2008001589A1 (de) |
IL (1) | IL202393A0 (de) |
MX (1) | MX2009012874A (de) |
NO (1) | NO20093536L (de) |
RU (1) | RU2009146882A (de) |
TN (1) | TN2009000490A1 (de) |
TW (1) | TW200908976A (de) |
WO (1) | WO2008145697A1 (de) |
ZA (1) | ZA200908247B (de) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至her2結構域ii之抗體及其酸性變異體的組合物 |
BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
EP3800204A1 (de) | 2013-04-16 | 2021-04-07 | F. Hoffmann-La Roche AG | Pertuzumab-varianten und evaluierung davon |
WO2018007554A1 (en) * | 2016-07-06 | 2018-01-11 | Pierre Fabre Medicament | Vinflunine and pd1 and/or pdl1 inhibitor as pharmaceutical combination |
MA47313B1 (fr) | 2017-01-17 | 2020-12-31 | Hoffmann La Roche | Formulations sous-cutanées d'anticorps her2 |
KR20190096384A (ko) | 2017-03-02 | 2019-08-19 | 제넨테크, 인크. | Her2-양성 유방암 어쥬번트 치료 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2707988B1 (fr) * | 1993-07-21 | 1995-10-13 | Pf Medicament | Nouveaux dérivés antimitotiques des alcaloïdes binaires du catharantus rosesus, leur procédé de préparation et les compositions pharmaceutiques les comprenant. |
FR2863891B1 (fr) * | 2003-12-23 | 2006-03-24 | Pf Medicament | Composition pharmaceutique de vinflunine destinee a une administration parentale, procede de preparation et utilisation |
-
2007
- 2007-05-31 EP EP07290679A patent/EP1997534A1/de not_active Ceased
-
2008
- 2008-05-05 US US12/602,127 patent/US20100196363A1/en not_active Abandoned
- 2008-05-12 TW TW097117418A patent/TW200908976A/zh unknown
- 2008-05-29 JP JP2010509824A patent/JP2010528091A/ja not_active Withdrawn
- 2008-05-29 BR BRPI0812280-6A2A patent/BRPI0812280A2/pt not_active IP Right Cessation
- 2008-05-29 RU RU2009146882/15A patent/RU2009146882A/ru not_active Application Discontinuation
- 2008-05-29 CA CA2689664A patent/CA2689664A1/en not_active Abandoned
- 2008-05-29 MX MX2009012874A patent/MX2009012874A/es not_active Application Discontinuation
- 2008-05-29 AU AU2008257555A patent/AU2008257555A1/en not_active Abandoned
- 2008-05-29 KR KR1020097025793A patent/KR20100017752A/ko not_active Application Discontinuation
- 2008-05-29 WO PCT/EP2008/056620 patent/WO2008145697A1/en active Application Filing
- 2008-05-29 CN CN200880017406A patent/CN101687104A/zh active Pending
- 2008-05-29 EP EP08760211A patent/EP2164573A1/de not_active Withdrawn
- 2008-05-30 CL CL2008001589A patent/CL2008001589A1/es unknown
- 2008-05-30 AR ARP080102281A patent/AR066778A1/es not_active Application Discontinuation
-
2009
- 2009-11-23 ZA ZA200908247A patent/ZA200908247B/xx unknown
- 2009-11-23 TN TNP2009000490A patent/TN2009000490A1/fr unknown
- 2009-11-29 IL IL202393A patent/IL202393A0/en unknown
- 2009-12-16 NO NO20093536A patent/NO20093536L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
ZA200908247B (en) | 2010-10-27 |
US20100196363A1 (en) | 2010-08-05 |
WO2008145697A1 (en) | 2008-12-04 |
AR066778A1 (es) | 2009-09-09 |
IL202393A0 (en) | 2010-06-30 |
RU2009146882A (ru) | 2011-07-10 |
EP2164573A1 (de) | 2010-03-24 |
CL2008001589A1 (es) | 2009-03-06 |
TW200908976A (en) | 2009-03-01 |
BRPI0812280A2 (pt) | 2014-11-18 |
CN101687104A (zh) | 2010-03-31 |
AU2008257555A1 (en) | 2008-12-04 |
CA2689664A1 (en) | 2008-12-04 |
KR20100017752A (ko) | 2010-02-16 |
NO20093536L (no) | 2009-12-16 |
TN2009000490A1 (en) | 2011-03-31 |
EP1997534A1 (de) | 2008-12-03 |
MX2009012874A (es) | 2010-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10478428B2 (en) | Combination therapy for cancer treatment | |
US10238630B2 (en) | Use of eribulin and poly (ADP ribose) polymerase (PARP) inhibitors as combination therapy for the treatment of cancer | |
EP3342411B1 (de) | Rapamycin-derivat zur behandlung von bauchspeicheldrüsenkrebs | |
JP2022017295A (ja) | Hdac阻害剤とpd-l1阻害剤との組み合わせ療法 | |
JP2010528091A (ja) | ビンフルニンおよびトラスツズマブを含んでなる癌治療の組合せ療法 | |
KR20170131491A (ko) | Ras 돌연변이와 관련된 암의 치료 방법 | |
Kelley et al. | Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide, and thoracic radiotherapy for limited-stage small-cell lung cancer, CALGB 30206 | |
TWI469776B (zh) | 有助於癌症之治療的方法,組成物以及製品 | |
Koukourakis et al. | Combined Irinotecan, Docetaxel and Conventionally Fractionated Radiotherapy in Locally Advanced Head and Neck Cancer. A. Phase I Dose Escalation Study | |
Dragnev et al. | A dose escalation trial of biweekly docetaxel and gemcitabine with filgrastim or pegfilgrastim for the treatment of patients with advanced solid tumors | |
JP2009509974A (ja) | 抗癌治療 | |
AU2018234141A1 (en) | Combination between trifluridine/tipiracil hydrochloride, an anti-tumor platinum complex, and an immune checkpoint modulator | |
US20190015393A1 (en) | The use of a temporary inhibitor of p53 for preventing or reducing cancer relapse | |
Patnaik et al. | ENZ-2208, a novel anticancer agent, in patients with advanced malignancies: a phase 1 dose-escalation study | |
US20140323576A1 (en) | Method for treating glioblastomas and other tumors | |
EA040587B1 (ru) | Способ лечения злокачественных новообразований | |
JP2010111582A (ja) | リファンピシンを成分とする肝臓癌治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110526 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110526 |
|
A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20111019 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20111019 |